I am a
Home I AM A Search Login

Migraine/Headache

Share this

Increased connectivity of pain matrix in chronic migraine: a resting-state functional MRI study.

To investigate the whole-brain resting-state functional connectivity in patients with chronic migraine (CM) using a data-driven method.

Learn More >

Histamine and migraine revisited: mechanisms and possible drug targets.

To review the existing literature on histamine and migraine with a focus on the molecule, its receptors, its use in inducing migraine, and antihistamines in the treatment of migraine.

Learn More >

Beta-Blockers for Migraine Prevention: a Review Article.

This review seeks to establish the role of beta-blockers (B-adrenergic receptor antagonists) in the pathophysiology of migraine prophylaxis, compare the efficacy of this group of medications with other common prophylactic agents, and also explore the relative benefits of using individual beta-blockers compared with others.

Learn More >

Antidepressants for Preventive Treatment of Migraine.

This review describes the pharmacology of each antidepressant class as it applies to migraine prevention, summarizes the evidence base for each medication, and describes relevant side effects and clinical considerations. Use of antidepressants for migraine prevention in clinical practice is also discussed.

Learn More >

Development of an education and self-management intervention for chronic headache – CHESS trial (Chronic Headache Education and Self-management Study).

Self-management interventions are well recognised and widely used in chronic conditions. Their application to chronic headaches has been limited and generally of low quality. We describe here our process for developing an evidence based, and theory driven, education and self-management intervention for those living with chronic headache.

Learn More >

Current Status of Antiepileptic Drugs as Preventive Migraine Therapy.

Antiepileptic drugs (AEDs) are an important class of agents used in the treatment of migraine, a neurological disorder that imparts significant socioeconomic burden. It is important for neurologists to understand the rationale for AEDs in migraine-preventive treatment, as well as each agent's efficacy and tolerability profile, in order to best determine clinical care.

Learn More >

Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists.

Migraine causes more years of life lived with disability than almost any other condition in the world and can significantly impact the lives of individuals with migraine, their families, and society. The use of medication for the prevention of migraine is an integral component to reducing disability caused by migraine. There are many different drug classes that have been investigated and shown efficacy in migraine prophylaxis. This article examines several of the classes of medications that are used for migraine preventive treatment, specifically, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, serotonin antagonists, alpha-adrenergic agonists, and N-methyl-D-aspartic acid receptor antagonists.

Learn More >

Paradoxical association between age and cerebrovascular reactivity in migraine: A cross-sectional study.

Previous studies reported an increased risk of ischemic stroke in younger migraineurs. We aimed to investigate the association between age and cerebrovascular reactivity (CVR) to vasodilatory stimuli in cerebral arteries in patients with migraine and normal controls.

Learn More >

Cerebrovascular reactivity in subjects with migraine: Age paradox?

Learn More >

CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review.

The purpose of the following review is to summarize the most recent understanding of migraine pathophysiology, as well as of basic and clinical science pharmacologic literature regarding the development of calcitonin gene receptor peptide (CGRP) antagonists as a novel therapeutic modality for the treatment of migraine headaches. A review is provided of erenumab, the first of its class FDA approved CGRP antagonist.

Learn More >

Search